182
CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.
 a patient: Subject; KS: Effect; 12 months: Treatment; imatinib 400 mg/d: Treatment; 12 months: Treatment.Time_elapsed; imatinib: Treatment.Drug; 400 mg/d: Treatment.Dosage
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient: Subject; KS: Effect; 12 months: Treatment; imatinib 400 mg/d: Treatment; 12 months: Treatment.Time_elapsed; imatinib: Treatment.Drug; 400 mg/d: Treatment.Dosage